These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 9130627)

  • 1. Treatment of Langerhans cell histiocytosis with 2 chlorodeoxyadenosine.
    Dimopoulos MA; Theodorakis M; Kostis E; Papadimitris C; Moulopoulos LA; Anastasiou-Nana M
    Leuk Lymphoma; 1997 Mar; 25(1-2):187-9. PubMed ID: 9130627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activity and toxicity of 2-CDA in Langerhans cell histiocytosis: a single institutional experience.
    Biswas G; Khadwal A; Arora B; Bhagwat R; Banavali SD; Nair CN; Pai SK; Kurkure PA; Parikh PM
    Indian J Cancer; 2007; 44(4):137-41. PubMed ID: 18322355
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Lenalidomide induced therapeutic response in a patient with aggressive multi-system Langerhans cell histiocytosis resistant to 2-chloro-deoxyadenosine and early relapsing after high-dose BEAM chemotherapy with autologous peripheral blood stem cell transplantation].
    Adam Z; Rehák Z; Koukalová R; Szturz P; Krejčí M; Pour L; Zahradová L; Moulis M; Kodet R; Nebeský T; Brejcha M; Adamová Z; Hájek R; Mayer J
    Vnitr Lek; 2012 Jan; 58(1):62-71. PubMed ID: 22448704
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complete remission of nodular pulmonary Langerhans cell histiocytosis lesions induced by 2-chlorodeoxyadenosine in a non-smoker.
    Aerni MR; Aubry MC; Myers JL; Vassallo R
    Respir Med; 2008 Feb; 102(2):316-9. PubMed ID: 17935961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 2-Chlorodeoxyadenosine (2-CDA) for the treatment of refractory or recurrent Langerhans cell histiocytosis (LCH) in pediatric patients.
    Stine KC; Saylors RL; Williams LL; Becton DL
    Med Pediatr Oncol; 1997 Oct; 29(4):288-92. PubMed ID: 9251735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term efficacy and safety of 2CdA (cladribine) in extra-pulmonary adult-onset Langerhans cell histiocytosis: analysis of 23 cases from the French Histiocytosis Group and systematic literature review.
    Néel A; Artifoni M; Fontenoy AM; Tessoulin B; Lorillon G; Cohen-Aubart F; Haroche J; Genereau T; de Menthon M; Guillevin L; Maillard H; Kahn JE; Hermine O; Araujo C; Dromer C; Jullien D; Hamidou M; Donadieu J; Tazi A
    Br J Haematol; 2020 Jun; 189(5):869-878. PubMed ID: 32191819
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of recurrent Langerhans cell histiocytosis in children with 2-chlorodeoxyadenosine.
    Mottl H; Starý J; Chánová M; Nekolná M; Drahokoupilová E; Smelhaus V
    Leuk Lymphoma; 2006 Sep; 47(9):1881-4. PubMed ID: 17065001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful treatment with 2-chlorodeoxyadenosine of refractory pediatric Langerhans cell histiocytosis with initial involvement of the gastrointestinal tract.
    Mayumi A; Imamura T; Sakamoto K; Ota T; Osone S; Usami I; Hosoi H
    Int J Hematol; 2019 Dec; 110(6):756-762. PubMed ID: 31350665
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of outcome for patients with mass lesions of the central nervous system due to Langerhans cell histiocytosis treated with 2-chlorodeoxyadenosine.
    Dhall G; Finlay JL; Dunkel IJ; Ettinger LJ; Kellie SJ; Allen JC; Egeler RM; Arceci RJ
    Pediatr Blood Cancer; 2008 Jan; 50(1):72-9. PubMed ID: 17455311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Langerhans cell histiocytosis with central nervous system involvement: follow-up by FDG-PET during treatment with cladribine.
    Büchler T; Cervinek L; Belohlavek O; Kantorova I; Mechl M; Nebesky T; Vorlicek J; Adam Z
    Pediatr Blood Cancer; 2005 Mar; 44(3):286-8. PubMed ID: 15481071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [MR-documented remission of pituitary stalk infiltration in patients with Langerhans cell histiocytosis following treatment with 2-chlorodeoxyadenosine].
    Vanícek J; Adam Z; Balsíková K; Krejcí M; Pour L; Szturz P; Zahradová L; Hájek R; Koukalová R; Rehák Z; Král Z; Mayer J
    Vnitr Lek; 2011 Oct; 57(10):871-5. PubMed ID: 22097697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gastrointestinal involvement in disseminated Langerhans cell histiocytosis (LCH) with durable complete response to 2-chlorodeoxyadenosine and high-dose cytarabine.
    Choi SW; Bangaru BS; Wu CD; Finlay JL
    J Pediatr Hematol Oncol; 2003 Jun; 25(6):503-6. PubMed ID: 12794533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cladribine (2-chlorodeoxyadenosine) in frontline chemotherapy for adult Langerhans cell histiocytosis: A single-center study of seven cases.
    Adam Z; Szturz P; Vaníček J; Moulis M; Pour L; Krejčí M; Hájek R; Mayer J
    Acta Oncol; 2013 Jun; 52(5):994-1001. PubMed ID: 22937955
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of children with Langerhans cell histiocytosis with 2-chlorodeoxyadenosine.
    Rodriguez-Galindo C; Kelly P; Jeng M; Presbury GG; Rieman M; Wang W
    Am J Hematol; 2002 Mar; 69(3):179-84. PubMed ID: 11891804
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment of Langerhans cells histiocytosis by cladribin reached long-term complete remission in 9 out of 10 adult patients].
    Adam Z; Szturz P; Duraš J; Pour L; Krejčí M; Rehák Z; Koukalová R; Navrátil M; Hájek R; Král Z; Mayer J
    Klin Onkol; 2012; 25(4):255-61. PubMed ID: 22920165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 2-Chlorodeoxyadenosine therapy for disseminated Langerhans cell histiocytosis.
    Pardanani A; Phyliky RL; Li CY; Tefferi A
    Mayo Clin Proc; 2003 Mar; 78(3):301-6. PubMed ID: 12630583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diabetes insipidus and Langerhans cell histiocytosis: a case report of reversibility with 2-chlorodeoxyadenosine.
    Ottaviano F; Finlay JL
    J Pediatr Hematol Oncol; 2003 Jul; 25(7):575-7. PubMed ID: 12847329
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 2'-Chlorodeoxyadenosine (2-CdA) as salvage therapy for Langerhans cell histiocytosis (LCH). results of the LCH-S-98 protocol of the Histiocyte Society.
    Weitzman S; Braier J; Donadieu J; Egeler RM; Grois N; Ladisch S; Pötschger U; Webb D; Whitlock J; Arceci RJ
    Pediatr Blood Cancer; 2009 Dec; 53(7):1271-6. PubMed ID: 19731321
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Langerhans cell histiocytosis with central nervous system involvement--complete response to 2-chlorodeoxyadenosine after failure of tyrosine kinase inhibitor therapies with sorafenib and imatinib.
    Baumann M; Cerny T; Sommacal A; Koeberle D
    Hematol Oncol; 2012 Jun; 30(2):101-4. PubMed ID: 21732400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of refractory Langerhans cell histiocytosis (LCH) with a combination of 2-chlorodeoxyadenosine and cytosine arabinoside.
    Apollonsky N; Lipton JM
    J Pediatr Hematol Oncol; 2009 Jan; 31(1):53-6. PubMed ID: 19125089
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.